Pharmacodynamics and pharmacokinetics of extended-release metformin in patients with type 2 diabetes and chronic kidney disease stage 3B

Diabetes Obes Metab. 2022 Jan;24(1):166-170. doi: 10.1111/dom.14554. Epub 2021 Oct 4.

Authors

Jean-Daniel Lalau^{1

2}, Youssef Bennis^{3

4}, Abdallah Al-Salameh^{1

2}, Anne-Sophie Hurtel-Lemaire³, Salha Fendri²

Affiliations

¹ Department of Endocrinology-Diabetes Mellitus-Nutrition, Amiens University Medical Center, Amiens, France.
² PériTox, UMR_I 01, University of Picardie Jules Verne, Amiens, France.
³ Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, France.
⁴ MP3CV Laboratory, UR UPJV 7517, University of Picardie Jules Verne, Amiens, France.

PMID: 34545662
DOI: 10.1111/dom.14554

No abstract available

Keywords: CGM variables; chronic kidney disease; lactate; metformin XR; pharmacokinetics; type 2 diabetes.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Delayed-Action Preparations / therapeutic use
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / pharmacokinetics
Hypoglycemic Agents / therapeutic use
Metformin* / pharmacokinetics
Metformin* / therapeutic use
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy

Substances

Delayed-Action Preparations
Hypoglycemic Agents
Metformin